Navigation Links
Rare Blood Vessel Disease Could Have New Treatment Option
Date:7/14/2010

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, July 14 (HealthDay News) -- A drug already used to treat lymphoma and rheumatoid arthritis shows promise as an option to treat rare forms of vasculitis, a disease affecting the blood vessels, according to two new studies.

The drug, rituximab, appeared to be as effective as the current standard, cyclophosphamide, in treating antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Rituximab may even be superior to cyclophosphamide in treating disease recurrences, the researchers found.

This is the first time in 40 years that a new drug has emerged to treat these conditions, according to the authors of the studies, both appearing in the July 15 issue of the New England Journal of Medicine.

"This trial has demonstrated for the first time there is an effective alternative to cyclophosphamide for remission induction, and there are a variety of results that make us think that rituximab should be the treatment of choice for remission induction," said Dr. John H. Stone, director of clinical rheumatology at Massachusetts General Hospital in Boston, referring to one of the studies, of which he was first author.

"I think these are two very important pivotal studies that bring hope to patients with ANCA vasculitis. And despite the fact that they are relatively small studies, they are proof of principle that this medicine has the ability to get rid of the group of cells that produce the [antibody]," added Dr. Ronald J. Falk, director of the University of North Carolina Kidney Center at Chapel Hill, and author of an accompanying editorial. "These antibodies are actually causing the disease, so by getting rid of them, one is really now attacking the disease cause rather than just disease symptoms."

"ANCA-associated vasculitis consists of two primary diseases, Wegener's granulomatosis and microscopic polyangitis," explained Stone.

The conditions are characterized by the presence of specific antibodies, which are made by plasma cells derived from B cells. These antibodies attack immune cells, leading to inflammation of the blood vessels that eventually affects the organs.

Rituximab targets B cells.

"Until the late [19]60s, early 70s, these were fatal diseases. We had no effective treatments at all," Stone said.

But at that time, the drug cyclophosphamide was shown to get the diseases under control, albeit at considerable cost, namely an increased risk of cancer, damage to the bladder, infections and infertility.

Since then, no other drug has emerged as a contender to cyclophosphamide, and so no head-to-head comparisons have been conducted.

"It was considered unethical up until now to perform such a trial," said Stone.

Stone and his team randomly assigned 197 patients with severe Wegener's granulomatosis or severe microscopic polyangitis to receive either rituximab or cyclophosphamide. Both groups were also taking glucocorticoids.

After six months, 64 percent of those in the rituximab arm and 53 percent in the cyclophosphamide were in remission and no longer needed steroids.

In patients who had relapsed, 67 percent of those receiving rituximab were in remission versus only 42 percent in the control group.

The trial was partially funded by Genentech, which makes rituximab.

The second research team, led by Dr. Rachel Jones of Addenbrooke's Hospital, Cambridge, U.K., randomly assigned 44 patients with newly diagnosed ANCA-associated vasculitis and kidney problems to rituximab or cyclophosphamide. Patients in both groups also took glucocorticoids.

Remission rates were similar in both arms: 76 percent of those taking rituximab and 82 percent of those taking cyclophosphamide.

But there was also a high rate of side effects in both groups (42 percent for rituximab and 36 percent for cyclophosphamide). Eighteen percent of patients in each group died.

Those results are sobering, Falk said. "Both studies had greater side effects than previously anticipated with rituximab. We would have hoped for far less deaths, so we need to proceed with caution," he said.

Both sets of study authors pointed out that larger and longer trials are needed to see how the drugs compare over the long haul.

More information

Visit the Vasculitis Foundation for more on this group of diseases.

SOURCES: John H. Stone, M.D., director, clinical rheumatology, Massachusetts General Hospital, Boston; Ronald J. Falk, M.D., director, University of North Carolina Kidney Center, Chapel Hill; July 15, 2010 New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Rare Blood Vessel Disease Could Have New Treatment Option
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology: